Payment overview · 2025
General Payments
$118.80
7 reported records · 5 companies
Healthcare provider profile · identity verified
Megan Green Carpenter
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CLARKSDALE, MS · NPI 1780157727
Verified facts
What the public records show
CMS Open Payments records show Megan Green Carpenter received $118.80 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 36.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.14 | 36.3% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $25.59 | 21.5% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $18.03 | 15.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.14 | 13.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.90 | 13.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $118.80 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $43.14 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $25.59 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 799 | 205 |
| Montelukast Sodium | Montelukast Sodium | 634 | 187 |
| Potassium Chloride | Potassium Chloride | 584 | 134 |
| Metformin Hcl | Metformin Hcl | 518 | 123 |
| Losartan Potassium | Losartan Potassium | 476 | 121 |
| Atorvastatin Calcium | Atorvastatin Calcium | 460 | 117 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 443 | 159 |
| Furosemide | Furosemide | 423 | 121 |
| Pantoprazole Sodium | Pantoprazole Sodium | 405 | 104 |
| Gabapentin | Gabapentin | 403 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 360 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 352 | 96 |
| Carvedilol | Carvedilol | 346 | 83 |
| Meloxicam | Meloxicam | 314 | 92 |
| Lisinopril | Lisinopril | 240 | 62 |
| Azithromycin | Azithromycin | 208 | 159 |
| Prednisone | Prednisone | 207 | 144 |
| Naproxen | Naproxen | 205 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 184 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 179 | 58 |
| Simvastatin | Simvastatin | 167 | 44 |
| Glipizide | Glipizide | 158 | 34 |
| Omeprazole | Omeprazole | 152 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 140 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 133 | 39 |
| Atenolol | Atenolol | 131 | 30 |
| Ibuprofen | Ibuprofen | 120 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 119 | 69 |
| Famotidine | Famotidine | 110 | 35 |
| Chlorthalidone | Chlorthalidone | 109 | 21 |
| Colchicine | Colchicine | 106 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 106 | 28 |
| Cephalexin | Cephalexin | 102 | 80 |
| Trazodone Hcl | Trazodone Hcl | 95 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 32 |
| Cefdinir | Cefdinir | 91 | 78 |
| Pioglitazone Hcl | Pioglitazone Hcl | 87 | 19 |
| Allopurinol | Allopurinol | 86 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 84 | 22 |
| Enalapril Maleate | Enalapril Maleate | 83 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 82 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 81 | 47 |
| Spironolactone | Spironolactone | 78 | 21 |
| Methocarbamol | Methocarbamol | 76 | 61 |
| Januvia | Sitagliptin Phosphate | 75 | 16 |
| Clonidine Hcl | Clonidine Hcl | 74 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 74 | 28 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 72 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 36 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 67 | 15 |
| Verapamil Er | Verapamil Hcl | 65 | 15 |
| Nifedipine Er | Nifedipine | 60 | 14 |
| Amoxicillin | Amoxicillin | 59 | 44 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 20 |
| Benazepril Hcl | Benazepril Hcl | 57 | 15 |
| Meclizine Hcl | Meclizine Hcl | 55 | 25 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 52 | 16 |
| Farxiga | Dapagliflozin Propanediol | 51 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 17 |
| Jardiance | Empagliflozin | 49 | 13 |
| Alprazolam | Alprazolam | 48 | 13 |
| Megestrol Acetate | Megestrol Acetate | 48 | 14 |
| Glipizide Er | Glipizide | 47 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 15 |
| Fluconazole | Fluconazole | 46 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 12 |
| Linzess | Linaclotide | 44 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 43 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 43 | 17 |
| Lorazepam | Lorazepam | 42 | 15 |
| Ozempic | Semaglutide | 42 | 14 |
| Methylprednisolone | Methylprednisolone | 41 | 38 |
| Terazosin Hcl | Terazosin Hcl | 41 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | 15 |
| Eliquis | Apixaban | 40 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 39 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 32 |
| Pregabalin | Pregabalin | 37 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 23 |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | 32 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | 12 |
| Mupirocin | Mupirocin | 29 | 26 |
| Baclofen | Baclofen | 28 | suppressed |
| Constulose | Lactulose | 28 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Lactulose | Lactulose | 28 | 15 |
| Ondansetron Odt | Ondansetron | 28 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Glyburide | Glyburide | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 18 |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Perphenazine | Perphenazine | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $118.80 · 7 records | ABBVIE INC. | NUZYRA, Omnipod, VRAYLAR, t:slim X2 Insulin Pump with Control-IQ | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error